Abstract:The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. To help address some of the main problems, the scientific community has designed vaccines, diagnostic tools and therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The rapid pace of technology development, especially with regard to vaccines, represents a stunning and historic scientific achievement. Nevertheless, many challenges remain to be overcome, such as improving vaccine and drug treatment efficacies for emergent mutant strains of SARS-CoV-2. Outbreaks of more infectious variants continue to diminish the utility of available vaccines and drugs. Thus, the effectiveness of vaccines and drugs against the most current variants is a primary consideration in the continual analyses of clinical data that supports updated regulatory decisions. The first two vaccines granted Emergency Use Authorizations (EUAs), BNT162b2 and mRNA-1273, still show more than 60% protection efficacy against the most widespread current SARS-CoV-2 variant, Omicron. This variant carries more than 30 mutations in the spike protein, which has largely abrogated the neutralizing effects of therapeutic antibodies. Fortunately, some neutralizing antibodies and antiviral COVID-19 drugs treatments have shown continued clinical benefits. In this review, we provide a framework for understanding the ongoing development efforts for different types of vaccines and therapeutics, including small molecule and antibody drugs. The ripple effects of newly emergent variants, including updates to vaccines and drug repurposing efforts, are summarized. In addition, we summarize the clinical trials supporting the development and distribution of vaccines, small molecule drugs, and therapeutic antibodies with broad-spectrum activity against SARS-CoV-2 strains.

Identification and Development of Therapeutics for COVID-19

Recent advances in small-molecular therapeutics for COVID-19

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

Therapeutic strategies for COVID-19: progress and lessons learned

Current Status of COVID-19 Therapies and Drug Repositioning Applications

Insights into Biological Therapeutic Strategies for COVID-19

Small molecules in the treatment of COVID-19

Current status of potential therapeutic candidates for the COVID-19 crisis

Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants

Pharmacological Therapies and Drug Development Targeting SARS-CoV-2 Infection

Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities

Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine

Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies

An Update on Current Therapeutic Drugs Treating COVID-19

Research Progress on Small-Molecule Drugs for Treating COVID-19

An in-depth analysis of COVID-19 treatment: Present situation and prospects

Medication Therapy Strategies for the Coronavirus Disease 2019 (COVID-19): Recent Progress and Challenges

COVID-19: Pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies.

Current and future therapeutical approaches for COVID-19